Key terms
About NUVB
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NUVB news
Apr 17
8:23am ET
Nuvation Bio price target raised to $5 from $4 at RBC Capital
Apr 17
6:30am ET
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX), Healthequity (HQY) and Nuvation Bio (NUVB)
Apr 12
6:55am ET
Strategic Acquisition Bolsters Nuvation Bio’s Growth Potential and Pipeline Prospects
Mar 28
8:16am ET
Nuvation Bio names Colleen Sjogren as Chief Commercial Officer
Mar 28
6:30am ET
Analysts Offer Insights on Healthcare Companies: Santhera Pharmaceuticals Holding (OtherSPHDF), Nuvation Bio (NUVB) and Mereo Biopharma Group Plc (MREO)
Mar 28
6:10am ET
Nuvation Bio price target raised to $8 from $5 at H.C. Wainwright
Mar 27
12:00pm ET
Nuvation Bio rises 30.6%
Mar 27
9:47am ET
Spotify initiated, Lowe’s downgraded: Wall Street’s top analyst calls
Mar 27
9:47am ET
Nuvation Bio rises 12.5%
Mar 27
6:06am ET
Nuvation Bio upgraded to Buy at Jefferies following acquisition of AnHeart
Mar 27
5:25am ET
Nuvation Bio upgraded to Buy from Hold at Jefferies
Mar 25
7:23am ET
Nuvation Bio Enhances Capabilities with AnHeart Merger Deal
Mar 25
7:19am ET
Nuvation Bio to acquire AnHeart Therapeutics in all-stock transaction
Mar 14
4:24pm ET
Nuvation Bio doses first patient in Phase 1/2 study of NUV-1511
Mar 07
6:27am ET
Nuvation Bio: A Strong Buy on Robust Financials and Promising Pipeline Catalysts
Mar 07
6:12am ET
Nuvation Bio price target raised to $5 from $4.50 at H.C. Wainwright
Mar 01
7:28am ET
RBC Capital Remains a Buy on Nuvation Bio (NUVB)
Mar 01
7:03am ET
BTIG Remains a Hold on Nuvation Bio (NUVB)
Feb 29
6:35pm ET
Buy Rating Affirmed for Nuvation Bio Amid Strong Financial Performance and Promising Clinical Progress
Feb 29
4:04pm ET
Nuvation Bio reports Q4 EPS (6c), consensus (10c)
No recent press releases are available for NUVB
NUVB Financials
Key terms
Ad Feedback
NUVB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NUVB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
